Protalix BioTherapeutics (PLX) 주식 개요
바이오 제약 회사인 프로탈릭스 바이오테라퓨틱스는 프로셀엑스 식물 세포 기반 단백질 발현 시스템을 기반으로 재조합 치료용 단백질의 개발, 생산 및 상용화에 종사하는 기업입니다. 자세히 보기
PLX Community Fair Values
Create NarrativeSee what 56 others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
Top Community Narratives
US$4.23
FV
52.0% 저평가 내재 할인율14.00%
Revenue growth p.a.
329
users have viewed this narrative0users have liked this narrative
0users have commented on this narrative
12users have followed this narrative
Protalix BioTherapeutics, Inc. 경쟁사
가격 이력 및 성과
| 과거 주가 | |
|---|---|
| 현재 주가 | US$2.03 |
| 52주 최고가 | US$3.19 |
| 52주 최저가 | US$1.32 |
| 베타 | -0.0094 |
| 1개월 변동 | -8.56% |
| 3개월 변동 | -33.66% |
| 1년 변동 | 23.03% |
| 3년 변동 | -2.87% |
| 5년 변동 | -30.00% |
| IPO 이후 변동 | -99.25% |
최근 뉴스 및 업데이트
내러티브 업데이트 • May 11
PLX: Extended Dosing Approval And 2026 Outlook Will Support Further Upside
Analysts kept their $11.00 price target on Protalix BioTherapeutics unchanged, citing only minor adjustments in discount rate, revenue growth, profit margin, and future P/E assumptions that did not materially alter their overall view of the stock. What's in the News The European Commission approved a 2 mg/kg every 4 weeks dosing regimen for pegunigalsidase alfa (Elfabrio) in adults with Fabry disease who are stable on enzyme replacement therapy, extending the infusion interval from every 2 weeks to every 4 weeks (Key Developments).내러티브 업데이트 • Apr 26
PLX: New Dosing Approval And 2026 Revenue Outlook Will Support Upside
Analysts now set Protalix BioTherapeutics' price target at $11.00. The unchanged level reflects only minimal tweaks to inputs such as the discount rate, long term revenue growth, profit margin assumptions and future P/E expectations.Recent updates
내러티브 업데이트 • May 11
PLX: Extended Dosing Approval And 2026 Outlook Will Support Further Upside
Analysts kept their $11.00 price target on Protalix BioTherapeutics unchanged, citing only minor adjustments in discount rate, revenue growth, profit margin, and future P/E assumptions that did not materially alter their overall view of the stock. What's in the News The European Commission approved a 2 mg/kg every 4 weeks dosing regimen for pegunigalsidase alfa (Elfabrio) in adults with Fabry disease who are stable on enzyme replacement therapy, extending the infusion interval from every 2 weeks to every 4 weeks (Key Developments).내러티브 업데이트 • Apr 26
PLX: New Dosing Approval And 2026 Revenue Outlook Will Support Upside
Analysts now set Protalix BioTherapeutics' price target at $11.00. The unchanged level reflects only minimal tweaks to inputs such as the discount rate, long term revenue growth, profit margin assumptions and future P/E expectations.내러티브 업데이트 • Apr 09
PLX: New Dosing Approval And 2026 Revenue Outlook Will Support Upside
Analysts have maintained their $11.00 price target for Protalix BioTherapeutics, citing relatively stable assumptions around fair value, discount rate, revenue growth, profit margin and future P/E as the basis for keeping their outlook unchanged. What's in the News The European Commission approves a 2 mg/kg every four weeks dosing regimen for pegunigalsidase alfa in adults with Fabry disease who are stable on enzyme replacement therapy, extending the infusion interval from every two weeks to every four weeks (Key Developments).내러티브 업데이트 • Mar 26
PLX: New Dosing Approval And 2026 Outlook Will Support Undervalued Upside
Analysts kept their $11.00 price target on Protalix BioTherapeutics unchanged, highlighting revised assumptions for revenue growth, profit margins, the discount rate and future P/E as key drivers behind their updated model. What's in the News Protalix BioTherapeutics issued 2026 total revenue guidance of approximately $78.0 million to $83.0 million, which includes a $25.0 million milestone payment from Chiesi tied to regulatory progress for Elfabrio (company guidance).내러티브 업데이트 • Mar 09
PLX: Extended Fabry Dosing Will Support Undervalued Long Term Outlook
Analysts have reiterated an $11.00 price target for Protalix BioTherapeutics, citing only slight tweaks to model inputs such as the discount rate, long-term revenue growth, profit margins, and future P/E assumptions rather than any major shift in their overall view. What's in the News Chiesi Global Rare Diseases and Protalix BioTherapeutics reported that the European Medicines Agency's Committee for Medicinal Product for Human Use issued a positive opinion recommending approval of a 2 mg/kg every 4 weeks dosing regimen of pegunigalsidase alfa for adult Fabry patients who are stable on enzyme replacement therapy (Key Developments).내러티브 업데이트 • Feb 23
PLX: Fabry Dosing Extension Will Support Undervalued Long Term Outlook
Analysts are maintaining their $11.00 price target for Protalix BioTherapeutics while slightly refining core modeling inputs such as the discount rate, long term revenue growth, profit margin and future P/E assumptions to better align with their updated risk and earnings outlook. What's in the News CHMP of the EMA issued a positive opinion recommending approval of a 2 mg/kg every 4 weeks dosing regimen for pegunigalsidase alfa in adult Fabry disease patients who are stable on enzyme replacement therapy, potentially giving eligible patients a longer interval between infusions (Product related announcement).내러티브 업데이트 • Feb 08
PLX: Renal ASO Pipeline And Fabry Dosing Expansion Will Drive Upside
Analysts have maintained their price target for Protalix BioTherapeutics at US$11.00, citing a combination of updated assumptions regarding the discount rate, revenue growth, profit margins, and a higher future P/E multiple as reasons to keep their existing valuation view. What's in the News Chiesi Global Rare Diseases and Protalix BioTherapeutics reported that the EMA's Committee for Medicinal Products for Human Use issued a positive opinion recommending approval of a 2 mg/kg every 4 weeks dosing regimen of pegunigalsidase alfa for adult Fabry patients who are stable on enzyme replacement therapy, aiming to extend time between infusions so patients can focus more on daily life (Key Developments).내러티브 업데이트 • Jan 24
PLX: Renal ASO Collaboration Will Drive Next Phase Of Upside Potential
Analysts have maintained their US$11.00 price target for Protalix BioTherapeutics, citing only slight adjustments to their discount rate, long term revenue growth, profit margin assumptions and future P/E outlook, rather than any major shift in their thesis. What's in the News Protalix BioTherapeutics and Secarna Pharmaceuticals entered a collaboration and option agreement to discover antisense oligonucleotide therapies targeting rare renal indications, with Secarna using its OligoCreator platform to design and profile candidates and Protalix selecting the biological targets (Key Developments).내러티브 업데이트 • Jan 10
PLX: Renal Collaboration Agreement Will Drive Next Phase Of Upside Potential
Analysts have maintained their fair value estimate for Protalix BioTherapeutics at US$11.00. This reflects only minor adjustments to assumptions around discount rate, revenue growth, profit margins and future P/E that do not materially change their overall view.내러티브 업데이트 • Dec 16
PLX: European Label Expansion Review Will Drive Next Phase Of Upside Potential
Analysts have nudged their price target on Protalix BioTherapeutics slightly higher to $11.00, reflecting marginal adjustments to discount rate, long term growth, and profitability assumptions, while maintaining a broadly consistent valuation framework. What's in the News Chiesi Global Rare Diseases and Protalix BioTherapeutics requested re examination of the EMA CHMP negative opinion on adding a once every 4 weeks 2 mg/kg Elfabrio dosing regimen to the currently approved every 2 weeks regimen, seeking broader label flexibility in Europe (Key Developments) Safety data from Elfabrio clinical trials highlighted hypersensitivity reactions in 14 percent of treated patients and anaphylaxis in 3 percent, underscoring the need for careful infusion monitoring and potential dose adjustments (Key Developments) Additional clinical observations included infusion associated reactions in 29 percent of Elfabrio patients and a reported case of membranoproliferative glomerulonephritis, prompting recommendations to monitor renal function and infusion related symptoms (Key Developments) Protalix BioTherapeutics was added to the S&P Global BMI Index, potentially increasing its visibility and accessibility to global institutional investors (Key Developments) Valuation Changes Fair value estimate maintained at $11.00 per share, indicating no change to the analyst target price.내러티브 업데이트 • Dec 02
PLX: European Regulatory Review Will Unlock Next Phase Of Upside Potential
Analysts have lowered their price target for Protalix BioTherapeutics from $12.50 to $11.00, citing a slight reduction in expected revenue growth and profit margins. What's in the News Protalix BioTherapeutics and Chiesi Global Rare Diseases have requested a re-examination of the negative opinion by the European Medicines Agency regarding the new dosing regimen for Elfabrio.내러티브 업데이트 • Nov 18
PLX: European Review Process Will Drive Next Phase Of Momentum
Analysts have lowered their price target for Protalix BioTherapeutics from $14.00 to $12.50. They cite more conservative expectations regarding revenue growth and profit margins.
새로운 내러티브 • May 19
Protalix BioTherapeutics aims for $3.20 by year-end amidst strong revenue growth
As of right now the stock as a current yield of about 2.42%, with a return on equity of about 6.79%. So a bit off of my goals of at least 5% and 10%. However over the last 3 years revenue has grown on
새로운 내러티브 • Apr 29
PRX-115 Trials And Elfabrio Launch Will Open Future Markets
Successful Phase II trials and Chiesi's involvement with Elfabrio could drive growth through new marketable products and increased market adoption.분석 기사 • Feb 22
Analysts Expect Protalix BioTherapeutics, Inc. (NYSEMKT:PLX) To Breakeven Soon
We feel now is a pretty good time to analyse Protalix BioTherapeutics, Inc.'s ( NYSEMKT:PLX ) business as it appears...분석 기사 • Jan 14
Have Insiders Been Buying Protalix BioTherapeutics, Inc. (NYSEMKT:PLX) Shares This Year?
It is not uncommon to see companies perform well in the years after insiders buy shares. Unfortunately, there are also...분석 기사 • Dec 10
Could The Protalix BioTherapeutics, Inc. (NYSEMKT:PLX) Ownership Structure Tell Us Something Useful?
A look at the shareholders of Protalix BioTherapeutics, Inc. ( NYSEMKT:PLX ) can tell us which group is most powerful...주주 수익률
| PLX | US Biotechs | US 시장 | |
|---|---|---|---|
| 7D | 1.5% | -1.6% | -0.8% |
| 1Y | 23.0% | 34.4% | 27.1% |
수익률 대 산업: PLX은 지난 1년 동안 34.4%의 수익을 기록한 US Biotechs 산업보다 저조한 성과를 냈습니다.
수익률 대 시장: PLX은 지난 1년 동안 27.1%를 기록한 US 시장보다 저조한 성과를 냈습니다.
주가 변동성
| PLX volatility | |
|---|---|
| PLX Average Weekly Movement | 8.9% |
| Biotechs Industry Average Movement | 11.0% |
| Market Average Movement | 7.2% |
| 10% most volatile stocks in US Market | 16.3% |
| 10% least volatile stocks in US Market | 3.2% |
안정적인 주가: PLX는 지난 3개월 동안 US 시장에 비해 주가 변동성이 크지 않았습니다.
시간에 따른 변동성: PLX의 주간 변동성(9%)은 지난 1년 동안 안정적이었습니다.
회사 소개
| 설립 | 직원 수 | CEO | 웹사이트 |
|---|---|---|---|
| n/a | 226 | Dror Bashan | www.protalix.com |
바이오 제약 회사인 프로탈릭스 바이오테라퓨틱스는 식물 세포 기반 단백질 발현 시스템인 프로셀엑스(ProCellEx)를 기반으로 재조합 치료용 단백질의 개발, 생산 및 상용화에 종사하고 있습니다. 이 회사는 고셔병 치료제 엘리소와 파브리병 진단을 받은 성인 환자 치료용 엘파브리오를 공급하고 있습니다. 또한 통풍 치료를 위한 2상 임상시험 중인 식물세포 발현 재조합 페길화 요산분해효소 PRX-115와 호중구 세포 외 트랩 질환 치료를 위한 식물세포 발현 페길화 재조합 인간 DNase I 제품 후보인 PRX-119를 개발 중입니다.
Protalix BioTherapeutics, Inc. 기초 지표 요약
| PLX 기초 통계 | |
|---|---|
| 시가총액 | US$161.95m |
| 순이익 (TTM) | US$15.33m |
| 매출 (TTM) | US$76.38m |
10.7x
주가수익비율(P/E)2.1x
주가매출비율(P/S)PLX는 고평가되어 있습니까?
공정 가치 및 평가 분석 보기순이익 및 매출
| PLX 손익계산서 (TTM) | |
|---|---|
| 매출 | US$76.38m |
| 매출원가 | US$41.83m |
| 총이익 | US$34.55m |
| 기타 비용 | US$19.22m |
| 순이익 | US$15.33m |
최근 보고된 실적
Mar 31, 2026
다음 실적 발표일
해당 없음
| 주당순이익(EPS) | 0.19 |
| 총이익률 | 45.24% |
| 순이익률 | 20.07% |
| 부채/자본 비율 | 0% |
PLX의 장기 실적은 어땠습니까?
과거 실적 및 비교 보기기업 분석 및 재무 데이터 상태
| 데이터 | 최종 업데이트 (UTC 시간) |
|---|---|
| 기업 분석 | 2026/05/21 08:04 |
| 종가 | 2026/05/21 00:00 |
| 수익 | 2026/03/31 |
| 연간 수익 | 2025/12/31 |
데이터 소스
당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.
| 패키지 | 데이터 | 기간 | 미국 소스 예시 * |
|---|---|---|---|
| 기업 재무제표 | 10년 |
| |
| 분석가 컨센서스 추정치 | +3년 |
|
|
| 시장 가격 | 30년 |
| |
| 지분 구조 | 10년 |
| |
| 경영진 | 10년 |
| |
| 주요 개발 | 10년 |
|
* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.
별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.
분석 모델 및 스노우플레이크
이 보고서를 생성하는 데 사용된 분석 모델에 대한 자세한 내용은 당사의 Github 페이지에서 확인하실 수 있습니다. 또한 보고서 활용 방법에 대한 가이드와 YouTube 튜토리얼도 제공합니다.
Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.
산업 및 섹터 지표
산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.
분석가 소스
Protalix BioTherapeutics, Inc.는 8명의 분석가가 다루고 있습니다. 이 중 2명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.
| 분석가 | 기관 |
|---|---|
| Ritu Baral | Canaccord Genuity |
| Raghuram Selvaraju | H.C. Wainwright & Co. |
| Peter Welford | Jefferies LLC |